Infection Clinical Trial
Official title:
Optimal Feeding Tube Dwell Time in VLBW Infants to Reduce Feeding Tube Contamination
Verified date | April 2024 |
Source | University of Florida |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study team will determine whether a decreased feeding tube dwell time will reduce feeding tube contamination
Status | Completed |
Enrollment | 151 |
Est. completion date | May 31, 2023 |
Est. primary completion date | February 2, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 30 Weeks to 40 Weeks |
Eligibility | Inclusion Criteria: - be born to a mother who is at least 18 years of age and English or Spanish speaking - born at < or equal to 30 weeks - have a birthweight < or equal to 1500 grams - be born to a mother who is COVID Negative - have a feeding tube placed within 24 hours of birth - be expected to require a feeding tube for 4 weeks following birth. Exclusion Criteria: - infant with known congenital GI anomalies - infants which are not expected to live - infants will be withdrawn from the study if they require abdominal surgery for GI morbidities |
Country | Name | City | State |
---|---|---|---|
United States | Unversity of Florida | Gainesville | Florida |
Lead Sponsor | Collaborator |
---|---|
University of Florida | National Center for Advancing Translational Sciences (NCATS), National Institute of Nursing Research (NINR) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Amount of Contamination | prepared solution of sectioned feeding tubes will be plated on Agar. After 24 hrs of incubation, unique colony types will be counted. | 24 hours | |
Secondary | Adverse Event Rate | The adverse events will be recorded and monitored during the NICU stay relating to sepsis, pneumonia and feeding intolerance, and necrotizing enterocolitis | up to 20 weeks | |
Secondary | Gastrointestinal Inflammation - Bio Rad | The samples will be analyzed for inflammatory markers using BioRad Bio-Plex platform | up to 20 weeks | |
Secondary | Gastrointestinal Inflammation - S100A12 | The samples will be analyzed for inflammatory markers using S100A12 | up to 20 weeks | |
Secondary | Gastrointestinal Inflammation - Calprotectin | The samples will be analyzed for inflammatory markers using calprotectin immunoassays | up to 20 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04529421 -
Assocation Between In-person Instruction and COVID-19 Risk
|
||
Recruiting |
NCT04081792 -
Optimal Antibiotics for Operated Diabetic Foot Infections
|
N/A | |
Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
Recruiting |
NCT04674657 -
Does Extra-Corporeal Membrane Oxygenation Alter Antiinfectives Therapy Pharmacokinetics in Critically Ill Patients
|
||
Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
Recruiting |
NCT00342589 -
New Techniques for Using a Saline Wash as a Diagnostic Tool for Pneumocystis Pneumonia
|
||
Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
Completed |
NCT03296423 -
Bacillus Calmette-guérin Vaccination to Prevent Infections of the Elderly
|
Phase 4 | |
Withdrawn |
NCT04217252 -
Clinical Application of High-throughput Sequencing Technology for the Diagnosis of Patients With Severe Infection
|
N/A | |
Recruiting |
NCT02905552 -
Myelodysplasic Syndromes and Risk Factors for Infection
|
N/A | |
Recruiting |
NCT02899143 -
Short-course Antimicrobial Therapy in Sepsis
|
Phase 2 | |
Withdrawn |
NCT02904434 -
Gastrointestinal Implications of Voriconazole Exposure
|
||
Active, not recruiting |
NCT02768454 -
Antimicrobials Stewardship by Pharmacist
|
N/A | |
Completed |
NCT02219776 -
Decreasing Infection In Arthroscopic Shoulder Surgery
|
N/A | |
Completed |
NCT02210169 -
RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates
|
N/A | |
Recruiting |
NCT02098226 -
Evaluation of MALDI Biotyper CA System for Detection of Gram- and Gram+ Bacteria and Yeasts
|
N/A | |
Completed |
NCT01846832 -
A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection
|
Phase 3 | |
Terminated |
NCT01441206 -
Safety and Pharmacokinetics of Single and Multiple Dose Rifampin in Infants
|
Phase 1 | |
Completed |
NCT01434797 -
Value of PET/CT Imaging in the Diagnosis of Permanent Central Venous Catheters Infection
|
||
Completed |
NCT01159834 -
Human Papillomavirus (HPV) Vaccination in Barretos (Pio XII Foundation - Barretos Cancer Hospital)
|
N/A |